Autophagy mediates hepatic GRK2 degradation to facilitate glucagon-induced metabolic adaptation to fasting.


Journal

FASEB journal : official publication of the Federation of American Societies for Experimental Biology
ISSN: 1530-6860
Titre abrégé: FASEB J
Pays: United States
ID NLM: 8804484

Informations de publication

Date de publication:
01 2020
Historique:
received: 12 06 2019
revised: 07 10 2019
accepted: 21 10 2019
entrez: 10 1 2020
pubmed: 10 1 2020
medline: 9 7 2020
Statut: ppublish

Résumé

The liver plays a key role during fasting to maintain energy homeostasis and euglycemia via metabolic processes mainly orchestrated by the insulin/glucagon ratio. We report here that fasting or calorie restriction protocols in C57BL6 mice promote a marked decrease in the hepatic protein levels of G protein-coupled receptor kinase 2 (GRK2), an important negative modulator of both G protein-coupled receptors (GPCRs) and insulin signaling. Such downregulation of GRK2 levels is liver-specific and can be rapidly reversed by refeeding. We find that autophagy, and not the proteasome, represents the main mechanism implicated in fasting-induced GRK2 degradation in the liver in vivo. Reducing GRK2 levels in murine primary hepatocytes facilitates glucagon-induced glucose production and enhances the expression of the key gluconeogenic enzyme Pck1. Conversely, preventing full downregulation of hepatic GRK2 during fasting using adenovirus-driven overexpression of this kinase in the liver leads to glycogen accumulation, decreased glycemia, and hampered glucagon-induced gluconeogenesis, thus preventing a proper and complete adaptation to nutrient deprivation. Overall, our data indicate that physiological fasting-induced downregulation of GRK2 in the liver is key for allowing complete glucagon-mediated responses and efficient metabolic adaptation to fasting in vivo.

Identifiants

pubmed: 31914606
doi: 10.1096/fj.201901444R
pmc: PMC7184883
mid: NIHMS1579716
doi:

Substances chimiques

Gastrointestinal Agents 0
Glucagon 9007-92-5
GRK2 protein, mouse EC 2.7.11.15
G-Protein-Coupled Receptor Kinase 2 EC 2.7.11.16

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

399-409

Subventions

Organisme : NIDDK NIH HHS
ID : R01 DK089883
Pays : United States

Informations de copyright

© 2019 Federation of American Societies for Experimental Biology.

Références

Proc Natl Acad Sci U S A. 2019 Apr 9;116(15):7449-7454
pubmed: 30910968
Exp Cell Res. 2011 Dec 10;317(20):2981-94
pubmed: 22001118
Br J Pharmacol. 2010 Jun;160(4):821-32
pubmed: 20590581
Mol Pharmacol. 2002 Aug;62(2):379-88
pubmed: 12130691
Sci Signal. 2015 Jul 21;8(386):ra73
pubmed: 26198359
Biochim Biophys Acta. 2014 Dec;1842(12 Pt A):2448-56
pubmed: 25239306
Expert Opin Drug Discov. 2019 May;14(5):421-431
pubmed: 30821530
Aging Cell. 2019 Feb;18(1):e12876
pubmed: 30430746
J Physiol. 2007 Feb 15;579(Pt 1):255-67
pubmed: 17053032
Autophagy. 2011 Jun;7(6):629-42
pubmed: 21460622
Sci Rep. 2017 Aug 16;7(1):8436
pubmed: 28814745
Anim Reprod Sci. 2007 Dec;102(3-4):194-207
pubmed: 17126505
J Cell Biol. 1967 Nov;35(2):C11-6
pubmed: 6055998
Autophagy. 2011 Jul;7(7):727-36
pubmed: 21471734
J Biol Chem. 2013 Jul 19;288(29):21074-81
pubmed: 23744068
J Mol Signal. 2014 Mar 06;9(1):1
pubmed: 24597858
J Biol Chem. 1998 Dec 25;273(52):35238-44
pubmed: 9857063
Int J Mol Sci. 2019 Mar 25;20(6):
pubmed: 30934608
Nat Rev Drug Discov. 2016 Nov;15(11):786-804
pubmed: 27516169
Gastroenterology. 2016 Feb;150(2):328-39
pubmed: 26453774
J Clin Invest. 2017 Aug 1;127(8):2941-2945
pubmed: 28650340
Arch Biochem Biophys. 1999 Jun 1;366(1):55-60
pubmed: 10334863
Cardiovasc Diabetol. 2016 Nov 10;15(1):155
pubmed: 27832814
Diabetologia. 2016 Jul;59(7):1376-1381
pubmed: 27115415
Dis Model Mech. 2012 Nov;5(6):804-11
pubmed: 22736456
Nature. 2001 Sep 13;413(6852):131-8
pubmed: 11557972
Pharmacol Ther. 2012 Jan;133(1):40-69
pubmed: 21903131
Nat Med. 2008 Jul;14(7):748-55
pubmed: 18542049
Cell Signal. 2018 Jan;41:25-32
pubmed: 28389415
Cells. 2017 Jun 08;6(2):
pubmed: 28594368
Nature. 2001 Sep 13;413(6852):179-83
pubmed: 11557984
Cell Signal. 2003 Nov;15(11):973-81
pubmed: 14499340
Cell. 2017 Mar 23;169(1):148-160.e15
pubmed: 28340340
Eur J Biochem. 1984 Aug 1;142(3):511-20
pubmed: 6432531
Methods. 2015 Mar;75:79-86
pubmed: 25644445
Nat Rev Gastroenterol Hepatol. 2017 Mar;14(3):170-184
pubmed: 28053338
Front Pharmacol. 2019 Feb 19;10:112
pubmed: 30837878
FEBS Lett. 1980 Sep 22;119(1):190-4
pubmed: 6253320
J Dairy Sci. 2006 May;89(5):1533-45
pubmed: 16606724
Hepatology. 2017 Mar;65(3):950-968
pubmed: 27880981
Nature. 1977 Nov 10;270(5633):174-6
pubmed: 927529
Biochim Biophys Acta Mol Basis Dis. 2018 Dec;1864(12):3655-3667
pubmed: 30261289
EMBO J. 2001 Sep 17;20(18):5129-38
pubmed: 11566877
J Dairy Sci. 2003 Sep;86(9):2895-903
pubmed: 14507025
J Pharmacokinet Pharmacodyn. 2015 Oct;42(5):541-52
pubmed: 26391023
EBioMedicine. 2016 Nov;13:132-145
pubmed: 27720394
Circulation. 2011 May 10;123(18):1953-62
pubmed: 21518983
J Endocrinol. 2008 Oct;199(1):5-19
pubmed: 18669612
Proc Natl Acad Sci U S A. 2010 Jan 19;107(3):1118-23
pubmed: 20080565
J Biol Chem. 1970 May 10;245(9):2375-83
pubmed: 5442278
Nat Rev Gastroenterol Hepatol. 2014 Mar;11(3):187-200
pubmed: 24192609

Auteurs

Marta Cruces-Sande (M)

Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa (UAM-CSIC), Madrid, Spain.
Instituto de Investigación Sanitaria La Princesa, Madrid, Spain.
CIBER de Enfermedades Cardiovasculares (CIBERCV), ISCIII, Madrid, Spain.

Alba C Arcones (AC)

Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa (UAM-CSIC), Madrid, Spain.
Instituto de Investigación Sanitaria La Princesa, Madrid, Spain.
CIBER de Enfermedades Cardiovasculares (CIBERCV), ISCIII, Madrid, Spain.

Rocío Vila-Bedmar (R)

Departamento de ciencias básicas de la salud, área de Bioquímica y Biología Molecular, URJC, Madrid, Spain.

Almudena Val-Blasco (A)

Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa (UAM-CSIC), Madrid, Spain.
Instituto de Investigación Sanitaria La Princesa, Madrid, Spain.
CIBER de Enfermedades Cardiovasculares (CIBERCV), ISCIII, Madrid, Spain.

Kfir Sharabi (K)

Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Department of Cell Biology, Harvard Medical School, Boston, MA, USA.

Daniel Díaz-Rodríguez (D)

Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa (UAM-CSIC), Madrid, Spain.

Pere Puigserver (P)

Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Department of Cell Biology, Harvard Medical School, Boston, MA, USA.

Federico Mayor (F)

Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa (UAM-CSIC), Madrid, Spain.
Instituto de Investigación Sanitaria La Princesa, Madrid, Spain.
CIBER de Enfermedades Cardiovasculares (CIBERCV), ISCIII, Madrid, Spain.

Cristina Murga (C)

Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa (UAM-CSIC), Madrid, Spain.
Instituto de Investigación Sanitaria La Princesa, Madrid, Spain.
CIBER de Enfermedades Cardiovasculares (CIBERCV), ISCIII, Madrid, Spain.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH